In today’s session Heron Therapeutics Inc (HRTX) registered an unusually high (547) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious HRTX increase. With 547 contracts traded and 6464 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: HRTX161118C00017500 closed last at: $1.15 or 155.6% up. About 180,663 shares traded hands. Heron Therapeutics Inc (NASDAQ:HRTX) has declined 6.53% since April 11, 2016 and is downtrending. It has underperformed by 12.68% the S&P500.
Heron Therapeutics Inc (NASDAQ:HRTX) Ratings Coverage
Out of 7 analysts covering Heron Therapeutics (NASDAQ:HRTX), 7 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $58 is the highest target while $40 is the lowest. The $52 average target is 175.86% above today’s ($18.85) stock price. Heron Therapeutics has been the topic of 11 analyst reports since August 3, 2015 according to StockzIntelligence Inc. The rating was maintained by Leerink Swann on Wednesday, September 23 with “Outperform”. Jefferies maintained the shares of HRTX in a report on Wednesday, September 23 with “Buy” rating. The firm has “Buy” rating given on Wednesday, October 26 by Aegis Capital. The rating was maintained by Brean Capital with “Buy” on Monday, August 10. The rating was maintained by Brean Capital on Monday, August 3 with “Buy”. Bank of America initiated the shares of HRTX in a report on Wednesday, September 2 with “Buy” rating. Lake Street initiated the stock with “Buy” rating in Thursday, December 10 report.
According to Zacks Investment Research, “Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA.”
Heron Therapeutics, Inc. is a biotechnology firm engaged in developing pharmaceutical products for patients suffering from cancer or pain. The company has a market cap of $763.52 million. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. It currently has negative earnings. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
HRTX Company Profile
Heron Therapeutics, Inc., incorporated on February 5, 1987, is a biotechnology company. The Firm is engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology (Biochronomer technology), which can deliver therapeutic levels of a range of otherwise short-acting pharmacological agents over a period of days to weeks with a single subcutaneous injection.
More news for Heron Therapeutics Inc (NASDAQ:HRTX) were recently published by: Businesswire.com, which released: “Heron Therapeutics Reports Financial Results for the Three and Nine Months …” on November 08, 2016. Nasdaq.com‘s article titled: “Oversold Conditions For Heron Therapeutics” and published on October 03, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.